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Abstract
Background: to evaluate the role of a risk stratification system in intermediate-risk prostate cancer (PCa) treated
with hypofractionated radiotherapy (HyRT).
Methods: 131 patients affected by intermediate-risk PCa were treated with HyRT at the total dose of 54,75 Gy in 15
fraction plus 9 months of androgen deprivation therapy (ADT). Patients were classified as favourable risk (FIR) if they
had a single NCCN intermediate-risk factor (IRF), a Gleason score ≤3 + 4 = 7, and <50 % of biopsy cores containing
cancer (PBCC). If these criteria were not met were classified as unfavourable risk (UIR). Univariate and multivariate
analyses using Cox proportional hazards model were calculated for biochemical recurrence-free survival (bRFS), the
risk of local recurrence and metastasis-free survival (MFS).
Results: After a median follow-up of 56.7 months (range 9.8 to 93.7 months), 11 patients (8.4 %) died, of whom 2
(1.5 %) for PCa. In the univariate analysis, Gleason score, PPBCs, IRFs and PSA at first follow-up were prognostic
factors for bRFS and LF while Gleason score, PPBCs and PSA at first follow-up were significant predictor for MFS. In
the multivariate analysis only the PSA at first follow-up resulted a prognostic factor for bRFS and MFS. Patients with
a value of PSA at first follow-up <0.7 ng/mL respect to those with PSA ≥0,7 ng/mL had a 5y-bRFS of 93.3 % vs. 57.
5 %, 5y-MFS of 99.0 % vs. 78.9 % and 5y-LF of 5.8 % vs. 38.3 %. Patients in the UIR PCa group with a PSA value <0.
7 ng/mL at first follow-up had significant better bRFS, LF and MFS.
Conclusions: Risk factors currently not included in the guidelines are useful to stratify patients with
intermediate-risk PCa in two groups of different prognosis even when HyRT is delivered. PSA at first follow-up is
useful in UIR PCa to guide the overall length of ADT.
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Background
Surgery and radiotherapy (RT) are the most commonly
used treatments in the management of prostate cancer
(PCa). Factor such as clinical stage, Gleason score and
the value of PSA at diagnosis are usually used to
categorize PCa in class of risk that are useful to guide
therapy [1].
Conformal high dose RT delivered with conventional
fractionation results in a significant biochemical control
with acceptable toxicities and currently represents the
standard therapy when RT is chosen as primary treat-
ment [2–5]. However, hypofractionated RT (HyRT) that
uses higher doses per fraction has been suggested as an
attractive option. In fact, due to the slow proliferation
rate of PCa cells that reflects in a lower α/β ratio than
the surrounding healthy tissue, the use of doses higher
than 2 Gy per fraction would give a therapeutic advan-
tage in terms of reduced late damage and/or higher local
control [6–8].
Unfortunately RT alone may not be sufficient for treat-
ing PCa and the addition of androgen deprivation ther-
apy (ADT) in association to radiation is often a
requisite. While ADT is not necessary in low-risk PCa as
radiation alone provides high clinical response, short
course ADT (i.e. for 4–6 months) and long course ADT
(i.e. for 2–3 years) are usually needed to treat intermedi-
ate and high-risk PCa, respectively [9–14]. Differently
from low and high-risk PCa, it has been suggested that
intermediate-risk PCa has a particularly inhomogeneous
behaviour with the consequence that the association of
short course ADT to RT may results in an overtreat-
ment or undertreatment of these patients [15].
Studies have found several predictors of outcome, cur-
rently not used to stratify PCa patients, that could be used
for this purpose such as the number of intermediate-risk
factors (IRFs), percentage of positive biopsy cores (PPBC),
the primary Gleason pattern [16–20]. On this basis, re-
cently a new classification for intermediate-risk PCa
has been proposed that divide this category in
favourable (FIR) and unfavourable intermediate-risk
(UIR) [21]. The proposed risk stratification is of im-
portance as it could have a clinical impact consider-
ing that FIR may beneficiate from RT alone as they
behave as low-risk PCa while UIR from RT in associ-
ation to ADT as they behave as intermediate or high-
risk PCa [15, 21].
In this study we evaluated the impact of the proposed
classification when HyRT is delivered, since this ap-
proach may be associated with hypothetical improved
local control respect to conventional fractionated RT, in
a population of patients with intermediate-risk prostate
cancer treated with the same HyRT schedule + ADT.
Moreover other variables that could be considered as
potential predictors of response were investigated.
Methods
Patients’ characteristics
Between March 2007 and March 2014, 131 consecutive
patients affected by intermediate risk prostate cancer were
evaluated. The data were prospectively collected and retro-
spectively analysed after the approval of our Institutional
Review Board (IRB) of Sant'Andrea Hospital. Written
consent was obtained from all patients. All patients had
histologically confirmed prostate cancer diagnosed with
transrectal ultrasound (TRUS) guided biopsies. For all
patients were obtained a complete history, physical examin-
ation with digital rectal examination, PSA level, total body
computed tomography scan with iodine-based contrast and
99mTc bone scan. Local staging was assessed with TRUS or
multiparametric magnetic resonance imaging (MRI) of the
pelvis including diffusion-weighted imaging and dynamic
contrast-enhanced study. According to the National Com-
prehensive Cancer Network (NCCN) guidelines, intermedi-
ate risk group includes patients with any clinical T2b–T2c
prostate cancer or Gleason Score equal to 7 or pre-
treatment PSA value ranging from 10 to 20 ng/mL [1].
PCa were classified as FIR if they had a single NCCN
IRF, a Gleason score ≤3 + 4 = 7, and <50 % of biopsy
cores containing cancer. If these criteria were not met,
PCa were classified as UIR [15, 21].
Simulation and treatment
The HyRT schedule used at our Institution has been pre-
viously described [22]. Briefly, all patients were immobi-
lized in the supine position. A pre-treatment CT scan
with 2.5 mm slices from the anal verge to the L5–S1
interface was obtained. MRI was used to better delineate
the Clinical Target Volume (CTV) when available. The
CTV1 included the prostate plus seminal vesicles and
the CTV2 the prostate alone. Planning Target Volumes
(PTV1 and PTV2, respectively) were generated with
8 mm margin in all directions except posteriorly where a
6 mm expansion was adopted in the first 36 patients. A
5 mm expansion in all direction was used in the other
patients as daily kv Cone Beam CT was used to verify
the patient position because of an implementation of the
linear accelerator. A 3D conformal radiotherapy (3D-
CRT) plan on the Eclipse planning system (Varian, Palo
Alto, CA) was performed with 5 coplanar fields and a 15
MV photons linear accelerator was used to deliver the
treatment. The PTV1 received 43.8 Gy in 12 fractions
and the PTV2 received 3 additional fractions of 3.65 Gy
for a total of 54.75 Gy in 15 fractions, three times a week
in order to avoid an excess of acute toxicity. Assuming a
α/β ratio of 1.5 Gy the total dose to the prostate is bio-
logically equivalent to 80.5 Gy delivered in 2 Gy/fraction.
Dose–volume constraints were as follows: V45 < 35 %
and V52 < 25 % for the rectum; V40 < 50 % for the blad-
der. Neoadjuvant, concomitant and adjuvant ADT was
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administered for a total of 9 months and was started
3 months before RT. ADT consisted in anti-androgen or
LHRH-analogue and was administered to all patients ac-
cording to the treating physician’s preference.
Toxicity and follow-up
The first follow up was performed after 6 month from
the start of the beginning of ADT (i.e. after 45–60 days
from the end of RT as the overall treatment time of RT
was of 5 weeks), then every 3 months for the first year
and every 6 months thereafter. Toxicities were assessed
at each visit according to the Radiation Therapy Oncol-
ogy Group (RTOG) scale for acute and late adverse ef-
fects [23]. Late toxicities were defined as occurring after
90 days from the end of treatment.
Statistical analysis
Comparison of between-groups characteristics (i.e. FIR
and UIR) was performed using the chi-square test or
Mann–Whitney U test. Receiver Operating Characteris-
tic curves were used to find cut-off values for continu-
ous variables. Biochemical failure was defined as the
PSA nadir after RT + 2 ng/mL according to the Phoenix
criteria [24]. Local recurrence was considered as the re-
lapse of the tumour in the prostate, seminal vesicles or
loco-regional lymph nodes at PET scan with choline,
MRI or biopsy. The median follow-up was calculated
using the “reverse” Kaplan-Meyer method [25]. Overall
survival (OS), cancer-specific survival (CSS), biochemical
recurrence-free survival (bRFS), the risk of local recur-
rence and metastasis-free survival (MFS) were calculated
after the end of RT until the event or the last follow-up
if the event did not occur. The curves were generated
using the Kaplan-Meier method. The Cox proportional
hazards model was used for both univariate and multi-
variate analysis. Significant variables in the univariate
analysis were assessed in the multivariate setting. Statis-
tical analyses were performed with SPSS statistical soft-
ware for Macintosh version 22.0 (SPSS, Inc., Chicago, IL).
A value of p ≤ 0,05 was considered statistically significant.
Results
Patients’ characteristics
The median age at diagnosis was 74 years (range 53–88).
Forty-nine patients were classified as FIR and 82 as UIR.
Twenty-nine patients (22.1 %) presented with T1c clin-
ical stage, 55 (42 %) with T2a, 28 (21.4 %) with T2b and
19 (14.5 %) with T2c. The median PSA at diagnosis was
9.0 ng/mL (range 0.9 to 19.99 ng/mL).
Thirty-five patients (26.7 %) had a Gleason score of
6(3 + 3), 67 (51.1 %) of 7(3 + 4) and the remaining 29
(22.1 %) of 7(4 + 3). Eighty-eight patients (67.2 %) were
treated with antiandrogen while in 43 patients (32.8 %) a
LHRH analogue was used. Patients’ characteristics are
shown in Table 1.
Toxicities
Overall, the treatment was well tolerated. Acute genito-
urinary (GU) toxicity of grade 1 occurred in 67 patients
(51.1 %), grade 2 in 14 patients (10.7 %) and grade 3 in 2
patients (1.5 %). Acute gastro-intestinal (GI) toxicity of
grade 1 were observed in 24 patients (18.3 %), grade 2 in
11 patients (8.4 %). None developed acute GI toxicity of
grade 3 or 4. Late GU toxicity occurred as follows: grade
1 in 46 patients (35.1 %), grade 2 in 11 patients (8.4 %),
grade 3 in 2 patients (1.5 %). Late GI toxicity of grade 1
was observed in 16 patients (12.2 %), grade 2 in 5 pa-
tients (3.8 %) and grade 3 in 1 patient (0.8 %).
Survival analysis
After a median follow-up of 56.7 months (range 9.8 to
93.7 months), 11 patients (8.4 %) died, of whom 9 for
intercurrent disease and 2 (1.5 %) for PCa. The 5-year
OS was 89.1 % (95%CI 83.2–95.6 %) and the 5-year CSS
was 97.6 % (95%CI 94.4–100 %). There were no differ-
ences between FIR and UIR in terms of OS (5y-OS FIR
85.6 % vs. 91.2 % UIR, p = 0.20) and CSS (CSS 5y FIR
100 % vs. 96.3 % UIR; p = 0.28). Because only 2 patients
died for PCa (both with UIR PCa), prognostic factors
where analysed only for bRFS, LF and MFS.
Fourteen patients (10.7 %) developed biochemical
recurrence after a median follow up of 29.5 months
(95 % CI 27.5 to 31.5 months). Of these patients,
thirteen (9.9 %) had also a clinical detectable disease
while in the remaining patient (0.8 %) ADT was
started due to the higher value of PSA. The 5y-bRFS
was 87.8 % (95%CI 81.8–94.4 %) and patients with
FIR had better bRFS than UIR (5y-bRFS 97.7 % vs.
82.5 %; p = 0.02) (Fig. 1). Among the 13 patients with
clinical recurrence, 7 (53.8 %) had local recurrence, 2
(15.4 %) developed distant metastases, and 4 (30.8 %)
had both local recurrence and distant metastases. Pa-
tients with clinical recurrence were treated as follows:
in 7 patients ADT alone was administered while RT
in association to ADT was used in 5 patients (2 pa-
tients with bone metastases were treated with pallia-
tive RT and 3 patients with recurrence to lymph-node
were treated with salvage RT to the involved lymph-
node station). The risk of LF at 5 years was 10.4 %
(95%CI 3.9–16.5 %) and was lower in patients with
FIR than those with UIR although this data was not
statistically significant (5y-LF 2.3 % vs. 15.0 %; p =
0.06). The 5y-MFS was 95.6 % (95%CI 91.9–99.5 %)
and was comparable in the two classes of risk (5y-
MFS 97.7 % vs. 94.4 %; p = 0.35).
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Prognostic factors
In the univariate analysis, Gleason score, PPBCs, IRFs
and PSA at the first follow-up were prognostic factors
for bRFS and LF while Gleason score, PPBCs and PSA at
first follow-up were significant predictor for MFS. On
the opposite, PSA at diagnosis, PSA after neoadjuvant
ADT but before RT and the type of HT were not signifi-
cant predictor for bRFS, LF or MFS. In the multivariate
analysis only PSA at first follow-up resulted as inde-
pendent prognostic factor for bRFS and MFS while was
not significant for LF (Table 2). Patients with a value of
PSA at first follow-up <0.7 ng/mL as compared to those
with PSA ≥0,7 ng/mL had a bRFS at 5 years of 93.3 %
vs. 57.5 %, 5y-MFS of 99.0 % vs. 78.9 % and 5y-LF of
5.8 % vs. 38.3 %. Conversely, the value of PSA after
3 months of neoadjuvant ADT was not a significant
factor despite all patients who developed recurrence
had a PSA value ≥0,35 ng/mL and were in the FIR
group (5y-bRFS FIR 100 % FIR vs. UIR 83.7 %; 5y-
MFS 100 % FIR vs. 94.2 % UIR; 5y-LF FIR 0 % vs.
13.9 % UIR).
The role of PSA at first follow-up was analysed in the
subgroup of patients with UIR PCa and patients with a
PSA value <0.7 ng/mL had significant better bRFS, LF
and MFS (Table 3). The data was not analysed in FIR
PCa because only one patient had biochemical relapse
and later developed also local recurrence and distant
metastasis.
Moreover, patients were stratified according to the
number of unfavourable risk factors (URF) (i.e. the num-
ber of IRFs, PPBC and the primary Gleason pattern). Pa-
tients with none or one URF had comparable outcomes
while patients with two or three URF had a poor prog-
nosis (5y-bRFS 97.8 % 0 URF vs. 97.2 % 1 URF vs.
65.5 % 2–3 URF, overall log-rank p <0.001; 5y-MFS
97.8 % 0 URF vs. 100 % 1 URF vs. 2–3 URF 87.9 %, over-
all log-rank p = 0.03; 5y-LF 2.2 % 0 URF vs. 2.9 % 1 URF
vs. 28 % 2–3 URF, overall log-rank p <0.001).
Table 1 Patients’ characteristics
Characteristics FIR (n = 49) UIR (n = 82) Total (n = 131) p value
n. % n. % n. %
Age
Median (range) 74 (55–84) 74 (53–88) 74 (53–88) 0,39
< 75 years 28 57,1 41 50,0 69 52,7 0,43
≥ 75 years 21 42,9 41 50,0 62 47,3
PSA at diagnosis
Median (range) 9,6 (0,9–19,0) 8,5 (0,9–19,99) 9,0 (0,9–19,9) 0,72
< 10 ng/mL 24 51,1 46 56,8 70 54,7 0,53
10–19,9 ng/mL 23 48,9 35 43,2 58 45,3
Clinical T stage
T1c 16 32,7 13 15,9 29 22,1 <0.001
T2a 32 65,3 23 28,0 55 42,0
T2b 1 2,0 27 32,9 28 21,4
T2c 0 0 19 23,2 19 14,5
Biopsy Gleason score
3 + 3 26 53,1 9 11,0 35 26,7 <0.001
3 + 4 23 46,9 44 53,7 67 51,1
4 + 3 0 0 29 35,4 29 22,1
PPBCs
< 50 % 49 100 39 47,6 88 67,2 <0,001
≥ 50 % 0 0 43 52,4 43 32,8
IRFs
< 2 49 100 23 28,0 72 55,0 <0,001
≥ 2 0 0 59 72,0 59 45,0
HT
Antiandrogen 32 65,3 56 68,3 88 67,2 0,72
LHRH analogue 17 34,7 26 31,7 43 32,8
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Discussion
In this study we analysed the outcome and the prognos-
tic factors for survival in a group of 131 patients with
intermediate-risk PCa treated with HyRT and ADT.
After a median follow-up of 56.7 months the 5-year
bRFS for the entire cohort was 87.8 % with 14 patients
that developed a biochemical recurrence of which 13
had also a clinical detectable relapse. Of these, 7
(53.8 %) had local recurrence, 2 (15.4 %), distant metas-
tases, and 4 (30.8 %) both local recurrence and distant
metastases. Eleven patients died of whom 2 because of
PCa (5-year OS 89.1 % and 5-year CSS 97.6 %).
Because of the heterogeneity of intermediate-risk PCa,
recently it has been postulated that these class of risk
could be further stratified into two groups with different
prognosis: favourable and unfavourable [15]. The sub-
classification in two groups with different prognosis
would be based on three main factors currently not in-
cluded in the classical stratification of PCa in three class
of risk: PPBCs, number of IRFs and the primary Gleason
pattern [21]. Several studies have shown that these three
factors have a prognostic value in terms of cancer spe-
cific survival, biochemical relapse, local and distant re-
currence [16–20]. Zumsteg et al. recently showed that
this stratification is useful when dose-escalated RT with
a conventional fractionation is delivered as FIR PCa rep-
resent a group of patients with favourable prognosis
comparable to that of low-risk PCa, while UIR PCa
tends to have a poor prognosis similar to patients af-
fected by high-risk PCa [21]. On this basis the authors
postulated that this classification could be used to
modulate the total duration of ADT [15, 21]. In our
study the three variables used to differentiate FIR and
UIR were statistically significant in the univariate ana-
lysis in terms of bRFS and LF, while all but IRFs were
statistical significant for MFS. Conversely, in the multi-
variate analysis all these factors were not significant but
this may be due to the relatively low number of events.
Moreover we did not analyse the impact of these factors
in terms of CSS since only 2 deaths were attributable to
PCa. However, is of interest that the 2 patients who died
for PCa were both affected by UIR PCa. To our know-
ledge this is the first study that confirmed the validity of
this new classification in intermediate-risk prostate can-
cer patients treated with high-dose HyRT although we
did not perform a direct comparison with patients af-
fected by low and high-risk PCa.
The role and duration of ADT, however, remains a
controversial issue. Patients with low-risk disease in fact,
should be treated with RT alone while high-risk patients
with RT and ADT for a total of 2–3 years (i.e. long-
course ADT). In a recent review the group of the
MSKCC proposes to use short-course ADT only in pa-
tients with unfavourable prognosis and RT alone in the
favourable prognosis group [15]. However, in the study
of Zumsteg et al., UIR PCa and in particular those with
≥2 unfavourable factors had a similar prognosis to pa-
tients with high-risk disease, while those with one risk
factor had an intermediate prognosis [21]. The authors
conclude that patients with 1 risk factor may beneficiate
Fig. 1 Cumulative incidence of bRFS among patients in favourable and unfavourable intermediate-risk
Bracci et al. Radiation Oncology  (2016) 11:78 Page 5 of 8
from short-course ADT and those with ≥2 risk factors
from long-course ADT as high-risk patients. Differently
from the study by Zumsteg et al., however, we did not
find any difference in terms of better prognosis among
patients with no risk factor and patients with a single
risk factor. Our results could be related to the intensified
treatment used and then in patients with 0 or 1
unfavourable risk factor would be necessary a longer
follow-up time to confirm this hypothesis.
We also analysed the role of PSA after three months
of neoadjuvant ADT as a lower PSA value could have a
predictive role in terms of better outcome. Zelefski et al.
in a retrospective study on more than one thousand PCa
patients showed that a PSA value <0.3 ng/mL reached
during neoadjuvant ADT is predictive of biochemical re-
currence, MFS and cancer-related survival [26]. The best
cut-off value we found was 0.35 ng/mL that is very simi-
lar to those found by Zelefski et al., however we did not
find differences between those who reached a PSA value
<0.35 ng/mL compared to those who had a higher value
even though all patients who developed biochemical re-
currence, local recurrence and distant metastases had a
PSA ≥0.35 ng/mL.
Finally we investigated the role of PSA at first follow-
up (i.e. after 6 months of ADT). In our protocol patients
are treated with ADT for nine months as we started this
protocol before there was evidence on the role of short-
course ADT in intermediate-risk PCa. In both univariate
and multivariate analysis, PSA at first follow-up was a
significant predictor of better bPFS and MFS while was
significant for the development of LF only in the univari-
ate analysis and of borderline significance in the multi-
variate analysis. Since all but one biochemical relapse
occurred in the UIR PCa group, we analysed his role
only in patients with unfavorable risk. In this subgroup




First Follow-up PSA (<0,7 vs. ≥0,7) 0,19 0,07–0,59 <0,01
LF
First Follow-up PSA (<0,7 vs. ≥0,7) 0,27 0,08–0,96 0,04
MFS
First Follow-up PSA (<0,7 vs. ≥0,7) 0,14 0,02–0,86 0,03
Table 2 Univariate and multivariate analyses according to bRFS, LF, MFS
Univariate analyses Multivariate analyses
bRFS HR 95%CI p-value HR 95%CI p-value
PSA at diagnosis (<10 vs. ≥10) 1,41 0,46–4,33 0,54
Gleason score (≤3 + 4 vs. 4 + 3) 0,15 0,05–0,46 <0,01 0,36 0,11–1,24 0,11
PPBCs (<50 % vs. ≥50 %) 0,14 0,04–0,51 <0,01 0,45 0,10–2,03 0,30
IRFs (<2 vs. ≥2) 0,13 0,03–0,58 <0,01 0,26 0,05–1,35 0,11
Pre RT PSA (<0,35 vs. ≥0,35) 0,03 0,01–4,76 0,18
PSA at First Follow-up (<0,7 vs. ≥0,7) 0,14 0,05–0,41 <0,01 0,28 0,09–0,88 0,03
HT (antiandrogen vs. LHRH analogue) 0,70 0,23–2,08 0,52
LF HR 95%CI p-value HR 95%CI p-value
PSA at diagnosis (<10 vs. ≥10) 1,32 0,37–4,68 0,67
Gleason score (≤3 + 4 vs. 4 + 3) 0,24 0,07–0,79 0,02 0,49 0,13–1,86 0,29
PPBCs (<50 % vs. ≥50 %) 0,22 0,06–0,83 0,03 0,63 0,13–3,16 0,57
IRFs (<2 vs. ≥2) 0,18 0,04–0,82 0,03 0,28 0,05–1,53 0,14
Pre RT PSA (<0,35 vs. ≥0,35) 0,03 0,01–9,79 0,24
PSA at First Follow-up (<0,7 vs. ≥0,7) 0,18 0,05–0,58 <0,01 0,30 0,08–1,13 0,07
HT (antiandrogen vs. LHRH analogue) 0,65 0,19–2,21 0,49
MFS HR 95%CI p-value HR 95%CI p-value
PSA at diagnosis (<10 vs. ≥10) 3,3 0,37–29,58 0,29
Gleason score (≤3 + 4 vs. 4 + 3) 0,15 0,03–0,82 0,03 0,33 0,05–2,03 0,23
PPBCs (<50 % vs. ≥50 %) 0,11 0,01–0,98 0,05 0,24 0,02–2,48 0,23
IRFs (<2 vs. ≥2) 0,43 0,08–2,33 0,33
Pre RT PSA (<0,35 vs. ≥0,35) 31,7 0,01– > 100 0,39
PSA at First Follow-up (<0,7 vs. ≥0,7) 0,09 0,02–0,50 <0,01 0,15 0,03–0,86 0,03
HT (antiandrogen vs. LHRH analogue) 0,39 0,08–1,91 0,24
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of patients a PSA value <0.7 ng/mL was a prognostic fac-
tor in terms of bPFS, LF and MFS (of note, the patient
who relapsed in the FIR group had a PSA ≥0.7 ng/mL).
Supported by these results we could hypothesise that
the duration of ADT in unfavourable PCa could be
modulated on the basis of early response to RT +
ADT. In fact, patients in the UIR group that reach a PSA
<0.7 ng/mL could discontinue ADT administration having
completed the 6 month of therapy (i.e. 3 months neoadju-
vant + 5 weeks of HyRT + 45–60 days after the end of
RT), while patients with a higher PSA value should be
treated as high-risk patients.
Our study presents several limitations. The median
follow-up time was almost 5 year, a relative short period
for a disease with a long natural history such as prostate
cancer. The relative low number of patients analysed
and the retrospective nature of the study are other limi-
tations. As we had only 2 patients that died because of
prostate, we were not able to analyse the role of prog-
nostic factor in terms of CSS, but only in terms of bRFS,
LF and MFS. However, we found that IRFs, PPBCs and
primary Gleason score were predictive of response in
the univariate analyses and are useful to differentiate FIR
and UIR also when HyRT is delivered.
Conclusions
In conclusion, HyRT is an attractive approach for the
treatment of prostate cancer. Using this strategy we are
potentially able to increase the therapeutic gain reducing
the risk of long-term toxicity and our data confirm this
postulation. Patients with intermediate-risk PCa repre-
sent a heterogeneous group of patients with a clinically
different disease and the use of prognostic factors cur-
rently not included in the guidelines is able to stratify
patients in two groups that have substantially a different
prognosis. In addition we found that PSA at first follow-
up is factor that could be used in UIR PCa to guide the
length of ADT administration. In light of these data, pa-
tients treated with HyRT affected by FIR PCa may bene-
ficiate of less aggressive treatments such RT alone
whereas patients with UIR PCa could be treated with
short-course or long-course ADT based on the early re-
sponse to the combined treatment. Prospective studies
conducted on large cohort of patients are needed to
confirm these data.
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